Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMT 28

Next Previous
Drug Profile

OMT 28

Alternative Names: 17,18-epoxyeicosatetraenoic acid analog; OMT-28

Latest Information Update: 04 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OMEICOS Therapeutics
  • Class Antiarrhythmics; Cardiovascular therapies; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Nitric oxide stimulants; Peroxisome proliferator-activated receptor alpha agonists; Phosphatidylinositol 3 kinase gamma modulators; Protein kinase stimulants; Proto-oncogene protein c-akt modulators; Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atrial fibrillation; Cardiomyopathies; Inflammation; Musculoskeletal disorders
  • Preclinical Wet age-related macular degeneration
  • No development reported Myocardial infarction

Most Recent Events

  • 29 Jan 2026 Efficacy and adverse events data from a phase II trial in primary mitochondrial disease released by OMEICOS Therapeutics
  • 29 Jan 2026 OMEICOS plans phase IIb/III study in PMD patients with myopathy and/or cardiomyopathy across European union and USA in second half of 2026
  • 30 Jul 2025 OMEICOS Therapeutics completes phase II PMD-OPTION trial for Musculoskeletal disorders, Cardiomyopathies and Inflammation in Germany, Italy and Netherlands (NCT05972954)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top